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Abstract
Background: Drug utilization review (DUR) programs are being conducted in Canadian hospitals
with the aim of improving the appropriateness of prescriptions. However, there is little evidence
of their effectiveness. The objective of this study was to assess the impact of both a retrospective
and a concurrent DUR programs on the quality of in-hospital prescribing.
Methods: We conducted an interrupted time series quasi-experimental study. Using explicit
criteria for quality of prescribing, the natural history of cisapride prescription was established
retrospectively in three university-affiliated hospitals. A retrospective DUR was implemented in
one of the hospitals, a concurrent DUR in another, whereas the third hospital served as a control.
An archivist abstracted records of all patients who were prescribed cisapride during the
observation period. The effect of DURs relative to the control hospital was determined by
comparing estimated regression coefficients from the time series models and by testing the
statistical significance using a 2-tailed Student's t test.
Results:  The concurrent DUR program significantly improved the appropriateness of
prescriptions for the indication for use whereas the retrospective DUR brought about no
significant effect on the quality of prescribing.
Conclusion: Results suggest a retrospective DUR approach may not be sufficient to improve the
quality of prescribing. However, a concurrent DUR strategy, with direct feedback to prescribers
seems effective and should be tested in other settings with other drugs.
Background
Prescription drugs constitute an important component of
health care. However, drugs can only benefit to patients if
they are used appropriately which involves that physi-
cians prescribe them according to evidence. One common
method of assessing and correcting the appropriateness of
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drug prescription is drug utilization review (DUR) pro-
grams [1-3].
In a retrospective DUR, observed patterns of drug pre-
scriptions together with an evaluation of their appropri-
ateness are sent to physicians in the form of a report of
collated practice patterns. Since the prescriptions assessed
were issued in the past, a retrospective DUR is relevant at
preventing inappropriate prescribing in the future [2]. A
DUR can also be run concurrently to the intervention. The
appropriateness of prescriptions is evaluated after the
drug has been dispensed but while the patient is still hos-
pitalized. The patient may then benefit from any correc-
tive action. Such action may take the form of individual
feedback from a pharmacist to the physician. A concurrent
DUR aims both at improving current prescribing patterns
and at preventing inappropriate prescribing in the future
[2].
The effectiveness of DUR programs has yet to be estab-
lished. The few evaluation studies of those programs con-
ducted until now have been criticized for lack of rigor. In
general, there are no adequate control groups and prior
trends in the quality of prescribing is not taken into
account [2,4-6]. The present study was designed to avoid
those limitations by comparing the effectiveness of retro-
spective and concurrent DUR to improve the quality of
physician drug prescriptions in hospital settings.
Methods
Design
We conducted an interrupted time-series quasi-experi-
mental study [7] in three hospitals. The natural history of
the prescription was established prior to the intervention
in two experimental hospitals. A retrospective DUR was
then implemented in one of the hospitals, a concurrent
DUR in another, whereas the third hospital served as a
control. The three hospitals are independently managed
from each other although they are all affiliated with Laval
University. They deliver tertiary care to a population of
around 750,000 inhabitants in Quebec City area.
Selection of the drug
To remain as close as possible to the routine clinical prac-
tice setting, the targeted drug was selected after consulting
pharmacists in all three settings to identify a drug that: 1)
would be a clinically relevant target for a DUR, 2) had
been prescribed in the hospitals for at least two years, 3)
had not been subjected to any prior DUR or intervention
aiming at modifying physicians prescribing behaviors,
Table 1: Criteria for the appropriate use of Cisapride
1. Indication for use
Criteria Exception
May be used: May be used
1.1 For empirical treatment (no investigation): symptoms of dysmotility 
with or without gastro-oesophagus reflux symptoms
1.1 1) If dysphagia, more than 3 vomiting episodes per week, or gastro-
intestinal bleeding not related to another cause
2) If mechanical obstruction or intestinal perforation.
1.2 For non empirical treatment (with investigation): symptoms of 
dysmotility with or without gastro-oesophagus reflux symptoms AND 
absence of moderate to severe oesophagitis at endoscopy (Savary-Miller 
grade III or IV)
1.2 1) For moderate to severe oesophagitis if prescribed with a proton 
pump inhibitor (lansoprazole, omeprazole, pantoprazole)
2) If mechanical obstruction or intestinal perforation.
1.3 For gastroparesia 1.3 If mechanical obstruction or intestinal perforation.
1.4 For chronic pseudo-obstruction 1.4 If mechanical obstruction or intestinal perforation.
2. Contra-indicated drugs (combination therapy)
Criteria Exception
Must not be used: May be used:
2.1 With domperidone or metoclopramide
2.2 With proton pump inhibitors 2.2 With proton pump inhibitors when moderate to severe oesophagitis
2.3 With an Anti-H2
3. Dosage
Criterion Exception
3.1 Maximum of 80 mg/day; 20 mg/dose, 4 doses/day 3.1 If > 80 years old or hepatic failure: Maximum of 40 mg/day; 10 mg/
dose
4. Drug interactions
Criterion Exception
Must not be used: 4.1 Concurrently with erythromycin, clarithromycin, 
fluconazol, ketoconazol, itraconazol, nefazodone, nicoumalone or 
warfarin
May be used: 4.1 In presence of nicoumalone or warfarin if international 
normalized ratio obtained 1 week after addition of cisapride and at 
cessation if stoppedBMC Health Services Research 2006, 6:33 http://www.biomedcentral.com/1472-6963/6/33
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and 4) was being prescribed at least ten times per month.
Cisapride was the only drug to meet these criteria in all
three settings. Cisapride is a gastrointestinal tract promo-
tility agent that was frequently used in Canada before its
withdrawal from the market in 2000, after completion of
this study.
Explicit criteria
Criteria for the appropriate prescription of cisapride were
made available to us by the Quebec hospitals network on
DUR [8]. The criteria had been developed by experts, and
approved by the network's scientific committee. We used
criteria pertaining to indication for use, combination ther-
apy, dosage, and drug interactions (Table 1). The Pharma-
cology and Therapeutic Committees in both the
concurrent and the retrospective DUR hospitals approved
those criteria.
Interventions
Retrospective DUR hospital
On March 2, 1998, the Pharmacy department in the retro-
spective DUR hospital distributed a newsletter informing
all physicians and pharmacists on the upcoming DUR on
cisapride. The newsletter included criteria for the appro-
priate prescribing of cisapride. Using the explicit criteria,
all prescriptions dispensed between March 16 and May
24, 1998 were retrospectively collected and assessed by a
pharmacist. Based on this assessment, on June 29, 1998, a
report of collated practice patterns of the appropriateness
of observed patterns of drug prescriptions was presented
in the Pharmacy Department newsletter that was distrib-
uted to clinicians in the hospital.
Concurrent DUR hospital
On May 4, 1998, criteria were distributed to all prescribers
and pharmacists in the concurrent DUR hospital. Between
May 11 and August 14, 1998, at the end of each day, a des-
ignated pharmacist had to screen all cisapride prescrip-
tions for appropriateness. When a prescription was
deemed inappropriate, the pharmacist had to communi-
cate directly with the physician to discuss the deviation
from criteria and propose alternative solutions. Physicians
were free to change their prescription. In February 1999,
the pharmacy department distributed a newsletter to phy-
sicians and pharmacists. The aggregate results on the qual-
ity of cisapride prescriptions issued during the 3-month
intervention period of May to August 1998 were presented
in this newsletter.
Data collection
We identified patient medical records using the computer-
ized pharmacy database of each hospital. In the control
hospital, we reviewed the records of patients who had
been prescribed cisapride between November 1994 and
Table 2: Average proportion of appropriate prescriptions on day 1 and day 4 of treatment during the observation period by hospital 
and by criterion of appropriateness
(95% Confidence Interval)
Criteria DUR hospital Number of 
prescriptions
Day 1 of treatment Day 4 of treatment
Indication for use concurrent† 771 82.27 (78.48 – 85.70) 84.51 (81.29 – 87.73)
retrospective‡ 692 65.54 (61.62 – 69.46) 76.04 (72.65 – 79.43)
control§ 1 040 76.77 (73.53 – 80.01) 83.20 (80.58 – 85.82)
Combination 
therapy
concurrent† 771 45.20 (40.95 – 49.45) 55.26 (51.52 – 59.00)
retrospective‡ 692 39.27 (35.64 – 42.90) 53.68 (49.54 – 57.82)
control§ 1 040 37.87 (33.86 – 41.88) 52.75 (49.40 – 56.10)
Dosage (not 
further analysed)
concurrent† 771 95.81 (94.53 – 97.09) 96.35 (95.16 – 97.54)
retrospective‡ 692 96.33 (94.94 – 97.72) 98.16 (97.03 – 99.29)
control§ 1 040 96.72 (95.59 – 97.85) 97.24 (96.20 – 98.28)
Drug Interactions 
(not further 
analysed)
concurrent† 771 98.00 (96.99 – 99.01) 98.41 (97.45 – 99.37)
retrospective‡ 692 96.97 (95.75 – 98.19) 96.88 (95.67 – 98.09)
control§ 1 040 97.34 (96.43 – 98.25) 98.37 (97,59 – 99.15)
† based on 52 months of observation
‡ based on 53 months of observation
§ based on 57 months of observationBMC Health Services Research 2006, 6:33 http://www.biomedcentral.com/1472-6963/6/33
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September 1999. There was no intervention in the control
hospital. In the retrospective DUR hospital, the period of
observation was from October 1994 to February 1999
with the first intervention implemented at the 41rst month
while the period of observation was from June 1995 to
September 1999 in the concurrent DUR hospital, with the
first intervention being implemented at the 35th month.
Periods of observation differed slightly among hospitals
mainly because pharmacy computer systems had not been
implemented at the same time in each hospital. Moreo-
ver, cisapride was de-listed in February 1999 from the hos-
pital formulary of the retrospective DUR hospital. A
medical archivist abstracted records of all patients who
were prescribed cisapride in each hospital during each
hospital study period. Information needed to apply DUR
criteria (see Table 1) was abstracted. Data included patient
age, gastro-intestinal diagnoses, symptoms and proce-
dures with date of occurrence, contra-indicated drugs, cis-
apride doses, date and time of administration,
international normalized ratios, and drugs interacting
with cisapride. Data was entered directly on a portable
computer using Epi-Info software. The archivist was not
aware of the study objectives and of the DUR criteria.
Appropriateness of use was later assessed using data col-
lected by the archivist. Explicit criteria were applied by
computer.
Analyses
Appropriateness of use
The unit of analysis is the monthly aggregated prescrip-
tions for all physicians in a given hospital. We divided the
study period into equal observation periods of four weeks.
For each period, we assessed the proportion of appropri-
ate prescriptions according to each one of the four criteria.
For each patient, the appropriateness of the cisapride pre-
scription was assessed both at the first day of treatment
(day 1) and three days later (day 4). This second day-4
assessment was performed to allow for the measurement
of the effect of the intervention during the course of treat-
ment in the concurrent intervention hospital.
We first estimated the overall average proportion of
appropriateness for the entire study period. This allowed
a general comparison of the percentage of appropriate
prescriptions according to each one of the criteria on day
1 and day 4 of treatment. Since appropriateness of pre-
scriptions was almost perfect as to dosage and drug inter-
actions at both day 1 and day 4, we did not carry out any
further analysis on these two criteria and concentrated on
the remaining two criteria: indication for use and combi-
nation therapy.
Time series
To test the effect of each type of DURs on the appropriate-
ness of cisapride prescriptions, we used ARIMA modeling
techniques [9-11]. For each hospital, we constructed 4
series of at least 52 observation periods (one series for
Table 3: Effects of the DURs on the appropriateness of prescriptions by type of interventions: indication for use
DUR experiment
hospitals
No DUR
 (control hospital)
Difference 
between
 DUR – no DUR
Type of 
DUR
Day of the 
evaluation
DUR 
intervention
ω0 (SE) P-value ω0 (SE) P-value T P-value
Retrospective Day 1 Criteria distribution 1.11 (4.87) 0.82 -6.36 (3.46) 0.07 1.25 0.21
Results diffusion 6.41 (5.62) 0.25 -7.02 (3.55) 0.05 1.71 0.09
Day 4 Criteria distribution -2.65 (4.20) 0.53 -2.46 (2.86) 0.39 0.04 0.97
Results diffusion 3.29 (4.91) 0.50 -3.04 (3.06) 0.32 1.09 0.28
Concurrent Day 1 Criteria 
distribution* and 
one-on-one 
interventions
5.90 (3.71) 0.11 -7.02 (3.55) 0.05 2.52 0.01
Results diffusion† 4.66 (4.90) 0.34 -5.17 (3.75) 0.17 1.30 0.20
Day 4 Criteria 
distribution* and 
one-on-one 
interventions
12.70‡ (5.71) 0.03 -4.08 (2.92) 0.16 2.62 0.01
Results diffusion 5.47 (4.58) 0.23 -2.98 (3.89) 0.44 1.41 0.16
* In the concurrent DUR, distribution of criteria corresponds to the start of the direct interventions 3-month period.
† Results were distributed in the form of a newsletter
‡ δ1 = -0.83 (SE = 0.25) P-value = 0.001BMC Health Services Research 2006, 6:33 http://www.biomedcentral.com/1472-6963/6/33
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each of the two criteria applied at day 1 and one series for
each of the two criteria applied at day 4).
ARIMA analysis
We estimated the ARIMA (autoregressive, seasonality, and
moving average) coefficients for the four series in each of
the three study hospitals. After obtaining a fitting model
for each of these 12 series, we created indicator series for
each experimental hospital. These latter series contained
only 0s and 1s, 0s for all time periods prior to the intro-
duction of the DUR in the hospital and 1 afterward. Since
two separate activities correspond to the introduction of
the DUR, the distribution of criteria and the diffusion of
the results, two series were created in each experimental
hospital. Four such series were created for the control hos-
pital, one corresponding to each of the experimental
series. Two coefficients were then introduced in the equa-
tions to model the interventions: t ω0 as an estimate of the
average differences in the proportion of appropriate pre-
scriptions (according to criteria) before and after the inter-
vention, and δ1 to estimate whether the effect of the
intervention is constant (δ1 = 0), expanding (δ1 > 0) or fad-
ing away (δ1 < 0).
In order to illustrate the evolution of the time series in a
way that is more illuminating, we built graphical repre-
sentations of the time series through a smoothing
method. In order to attenuate the noise created by the ran-
dom components in the raw data, we used Tukey's
smoothing procedure [12]. This lag 3 smoothing tech-
nique consists in replacing the Ith value in the series with
the mean of the i-1, i and i+1 values. For each series, we
performed 3 mean smooths with a lag of 3. It should be
noted that the purpose of the graphic representations is
for ease of interpretation only, the ARIMA models were
built using raw data, and the parameters of the models
were used to draw the conclusions about the effect of the
DUR on prescriptions appropriateness.
Proportion of cisapride prescriptions appropriate at day 1 in regards of indication for use in the concurrent DUR, retrospec- tive DUR and control hospitals between October 1997 and October 1999 Figure 1
Proportion of cisapride prescriptions appropriate at day 1 in regards of indication for use in the concurrent DUR, retrospec-
tive DUR and control hospitals between October 1997 and October 1999.BMC Health Services Research 2006, 6:33 http://www.biomedcentral.com/1472-6963/6/33
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Statistical analysis
We used t-tests to compare the ω0 coefficients of the exper-
imental series with those of the control series. A signifi-
cant t indicates a significant intervention effect over and
above the secular trend captured by the variation in the
control series. We conducted the analyses using the SAS
software package [13].
Results
For each hospital, the overall average proportion of
appropriate prescriptions by criterion of appropriateness
is displayed in Table 2. For the entire study period, appro-
priateness was almost perfect with regards to dosage and
drug interactions at both day 1 and day 4 in all three hos-
pitals. For the other two criteria, appropriateness seems to
be improving between day 1 and day 4 in all hospitals
including the control one. Overall, appropriateness was
higher on indication for use than on combination therapy
criterion.
Table 3 reports the effect of each DUR intervention on the
appropriateness of prescriptions for the indication for use.
Time-series results are also presented for the control hos-
pital. Since all omega values but one are positive in both
DUR experimental hospitals, it describes a general ten-
dency for improvement whereas this tendency is toward
reduced appropriateness in the control hospital in which
omega values are all negative. In the concurrent DUR hos-
pital, the improvement induced by the distribution of cri-
teria and the start of pharmacist interventions is
statistically significant for prescriptions at day 4, but not
at day 1. Figures 1 and 2 depict these time series and the
timing of the interventions. It shows that, during the
direct interventions period conducted in the concurrent
Proportion of cisapride prescriptions appropriate at day 4 in regards of indication for use in the concurrent DUR, retrospec- tive DUR and control hospitals between October 1997 and October 1999 Figure 2
Proportion of cisapride prescriptions appropriate at day 4 in regards of indication for use in the concurrent DUR, retrospec-
tive DUR and control hospitals between October 1997 and October 1999.BMC Health Services Research 2006, 6:33 http://www.biomedcentral.com/1472-6963/6/33
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DUR hospital, the appropriateness of prescriptions for the
indication for use has decreased in the control hospital.
The graphical representations are concordant with the
respective negative omega values reported in Table 3. In
contrast, during this same period in the concurrent DUR
hospital, the appropriateness of prescriptions has
remained stable at day 1 and increased at day 4. Again, the
graphical representations are concordant with the omega
values reported in Table 3. At day 1, the omega value was
positive although not statistically significant (P value of
0.11) whereas it was both positive and statistically signif-
icant when prescriptions were assessed after the initiation
of treatment at day 4 (P value of 0.03). When these
changes are compared with those in the control hospital
(see Table 3), there is a statistically significant improve-
ment at both day 1 (T = 2.52; P = 0.01) and day 4 (T =
2.62; P = 0.01) in the concurrent DUR hospital only. This
improvement is associated with the distribution of criteria
to physicians and pharmacists as part of the DUR pro-
gram.
The effect of the DUR interventions on the appropriate-
ness of combination therapy is presented in Table 4 and
depicted in Figures 3 and 4. In all settings the appropriate-
ness has decreased over the study period as illustrated by
the fact that 15 of the 16 omega values are negative. More-
over, this decrease seems to be more pronounced in the
concurrent DUR hospital in which it is statistically signif-
icant after the diffusion of collated results at both day 1
(ω0 = -16.72; P = 0.01) and 4 (ω0 = -14.29; P = 0.04).
There is however no statistically significant difference
between the control hospital and the two others.
Discussion
Three important findings emerge from this evaluation.
First, conducting a retrospective DUR program had no sig-
nificant effect on prescription quality. Second, the concur-
rent DUR program is associated with a significant
improvement of the appropriateness of prescriptions for
the indication for use. Third, in all hospitals the appropri-
ateness for combination therapy decreased over the study
period.
Dissemination of the criteria and of collated results to cli-
nicians were the only interventions in the retrospective
DUR hospital. Therefore it may explain the lack of effec-
tiveness of this approach. Although dissemination of cri-
teria may predispose physicians to modify their
prescribing behavior, it may not be sufficient. Previous
studies have shown that guidelines dissemination alone
has no significant effect on prescribing behavior [14]
while studies assessing the impact of DUR intervention
letters or reports on prescribing for patients not specifi-
cally identified in the letter or report cannot be found in
the literature [6]. In theory, such report could reinforce
the prescribing behavior change though our results sug-
gest it is not sufficient.
In addition to the dissemination of criteria, the concur-
rent DUR interventions included direct communication
between the pharmacist and the physician during the
course of treatment, and the distribution of collated
results. As indicated above, disseminating criteria may
predispose physicians to behavior change while the other
two activities may enable and reinforce the change,
Table 4: Effects of the DURs on the appropriateness of prescriptions by type of interventions: combination therapy
DUR experiment
 hospitals
No DUR
 (control hospital)
Difference 
between
 DUR – no DUR
Type of DUR Day of the 
evaluation
DUR intervention ω0 (SE) P-value ω0 (SE) P-value T P-value
Retrospective Day 1 Criteria distribution -3.46 (4.48) 0.44 -11.56 (8.96) 0.20 0.81 0.42
Results diffusion -2.14 (5.26) 0.68 -5.93 (9.33) 0.53 0.35 0.73
Day 4 Criteria distribution -2.98 (5.12) 0.56 -7.58 (4.22) 0.07 0.69 0.49
Results diffusion 1.08 (6.01) 0.86 -11.73 (4.20) 0.01 1.75 0.08
Concurrent Day 1 Criteria distribution* 
and one-on-one 
interventions
-10.75 (5.74) 0.06 -10.04 (8.93) 0.26 -0.07 0.94
Results diffusion† -16.72 (6.45) 0.01 -2.68 (7.59) 0.72 -1.41 0.16
Day 4 Criteria distribution* 
and one-on-one 
interventions
-4.71 (5.59) 0.40 -7.69 (4.32) 0.08 0.42 0.81
Results diffusion -14.29 (6.80) 0.04 -5.85 (5.87) 0.32 -0.94 0.35
* In the concurrent DUR, distribution of criteria corresponds to the start of the direct interventions 3-month period.
† Results were distributed in the form of a newsletterBMC Health Services Research 2006, 6:33 http://www.biomedcentral.com/1472-6963/6/33
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respectively. Our results suggest that as a package these
three interventions may be sufficient to induce prescribing
behavior change in physicians. This effect was however
limited to the indication for use criterion.
The appropriateness of prescriptions with regards to com-
bination therapy decreased in all hospitals over the study
period. As the decrease in appropriateness was also
observed in the control hospital, it suggests a strong secu-
lar trend that would have been interpreted wrongly as an
adverse effect of the interventions had we conducted this
study without an adequate control group. Secular trends
in prescribing behavior have been observed in the past
[15].
This overall decrease in appropriateness for the combina-
tion therapy criterion was not expected. As reports of
adverse events have been published during the study
period, it may have influenced physicians and pharma-
cists to focus more on the indication for use than on com-
bination therapy. In July 1996, in a newsletter sent to
physicians and pharmacists Health Canada informed that
cisaprise was contraindicated in patients taking drugs that
inhibited the cytochrome P450-3A4 enzymes that metab-
olize cisapride or in those taking drugs that could prolong
the QT interval since those patients were at increased risk
of developing severe ventricular arythmia or torsades de
pointe. The list of all drugs – including cisapride- that
could prolong the QT interval or torsades de pointe
appeared in another newsletter sent to health profession-
als in January 1998. These warning newsletters may have
had an effect on the prescribing behavior of physicians in
our study although previous research has shown such let-
ters alone had no effect [16]. In the USA, change in labe-
ling, black-box warning and press release by the FDA,
together with a "Dear Health Care Professional" letter sent
by the manufacturer to physicians and pharmacists
showed no effect in reducing prescribing of contraindi-
Proportion of cisapride prescriptions appropriate at day 1 in regards of combination therapy in the concurrent DUR, retro- spective DUR and control hospitals between October 1997 and October 1999 Figure 3
Proportion of cisapride prescriptions appropriate at day 1 in regards of combination therapy in the concurrent DUR, retro-
spective DUR and control hospitals between October 1997 and October 1999.BMC Health Services Research 2006, 6:33 http://www.biomedcentral.com/1472-6963/6/33
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cated drugs to patients on cisapride [17]. Although similar
actions are not likely to have impact differently on Cana-
dian physicians and pharmacists, the feedback messages
on the combination therapy criterion in our study, if any,
may thus have been perceived as clinically unimportant.
Indeed, the concomitant prescription of cisapride with a
proton pomp inhibitor although inappropriate is not
dangerous. On the other hand, physicians seem to have
considered very seriously the inappropriateness of pre-
scribing concomitantly cisapride and contraindicated
drugs, as illustrated by the very high proportion of pre-
scriptions being appropriate on this criterion.
Our results also show that the appropriateness of prescrip-
tions has improved in all settings and for both criteria
between day 1 and day 4. It suggests that either physicians
are reviewing their own prescriptions and/or pharmacists,
as part of their usual practice, are intervening even in the
absence of a formal DUR program [18]. This strong
improvement effect illustrates the importance of a control
group when one wants to assess the effect interventions
have during the course of a treatment [14].
Our study has strengths and limitations. The greatest
strength of this study is the use of a control-group time-
series analysis design based on records of drug prescrip-
tions for a period of over four years. We were therefore
able to account for prior trends and for regression toward
the mean i.e., the tendency for deviant prescriptions to
approach the mean on subsequent observation [14].
Moreover, this study was conducted in the context of cur-
rent clinical practice with no attempt from the investiga-
tors to impose the selection of the drug or to enhance
compliance of pharmacist in delivering DUR interven-
tions. As a limitation however, there was a lack of rand-
omization. In addition, because no information on
prescribing physicians was collected it was not possible to
describe physician characteristics in each hospital and test
Proportion of cisapride prescriptions appropriate at day 4 in regards of combination therapy in the concurrent DUR, retro- spective DUR and control hospitals between October 1997 and October 1999 Figure 4
Proportion of cisapride prescriptions appropriate at day 4 in regards of combination therapy in the concurrent DUR, retro-
spective DUR and control hospitals between October 1997 and October 1999.BMC Health Services Research 2006, 6:33 http://www.biomedcentral.com/1472-6963/6/33
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their comparability. Another limitation lies in the fact that
the unit of analysis is a hospital level aggregation of pre-
scriptions. Although this insures the reliability of our
observations of the proportion of appropriate prescrip-
tions, their number was still relatively modest thus limit-
ing the power to detect an intervention effect. Finally, the
concurrent DUR interventions lasted only three months.
The effect of this type of DUR could therefore have been
greater had we assessed a program implemented on a
longer term. It is however current practice in Quebec hos-
pitals to conduct concurrent DUR programs of short dura-
tion, in general six weeks [19].
Care should be taken before generalizing the results of
this study to all DUR programs as the effect of those pro-
grams depends heavily on the targeted drug, the interven-
tions offered as part of the programs, and on the criterion
against which appropriateness is assessed. There is also a
need for further research to assess whether the effect of
DUR interventions on the drug prescribing process impact
on patient outcomes and on the efficiency of health care
services.
The decrease in the appropriateness of prescriptions for
combination therapy highlights the need to design or
integrate more effective interventions. In this regard, as
part of a concurrent DUR program, computer-based inter-
ventions look promising. Systems designed to warn phar-
macists about the inappropriate prescription of a drug
have been shown to contribute at improving ambulatory
prescribing patterns for the elderly patients [20]. Compu-
ter physician order entry displaying drug utilization rec-
ommendations could also be integrated in DUR programs
[21]. There is also increasing evidence that providing phy-
sicians with prescriber-specific and patient-specific pro-
files positively alter the prescribing behavior of physicians
in the ambulatory setting [22-24]. To achieve greater
impact, all the preceding interventions could be offered in
concert with other well established interventions such as
academic detailing [25]. Further research is needed to
identify the mix of interventions that would be the most
cost-effective.
Conclusion
In conclusion, we have conducted this study in the rou-
tine clinical practice setting with no intervention from us
in the clinical process. Although cisapride has since been
withdrawn from the Canadian market, this study is rele-
vant as it shows that a retrospective DUR the way it is gen-
erally conducted in Canadian hospitals may not be
sufficient to improve the quality of prescribing. On the
other hand, a concurrent DUR with direct feedback to pre-
scribers seems effective to improve the appropriateness
with regard to the indication for use. Nevertheless, it may
have negative effects on other component of the quality of
the prescriptions. Since the effect of DURs varies with
both the type of interventions conducted and the criterion
applied, there is a need for further research in other set-
tings and with other drugs.
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